Updated Monday, 4/25.
The April IPO market is expected to close out with norovirus vaccine developer HilleVax (HLVX), along with two healthcare micro-caps. Other small deals and SPACs may join the calendar during the week.
HilleVax (HLVX) plans to raise $175 million at a $625 million market cap. Formed through the collaboration of Frazier and Takeda Pharmaceuticals, the company is developing a virus-like particle based vaccine candidate for the prevention of gastroenteritis caused by norovirus infection. An open IND was transferred from Takeda in September 2021, under which HilleVax plans to initiate a Phase 2b trial in infants in the 2Q22, with top-line data expected in the 2H23.
Biotech Belite Bio (BLTE) plans to raise $36 million at a $145 million market cap. Belite is developing novel therapies for untreatable eye diseases involving retinal degeneration, as well as metabolic diseases. Its lead candidate is being developed for autosomal recessive Stargardt disease and is currently in a Phase 2 trial in Australia and Taiwan.
Surgical implant maker Tenon Medical (TNON) plans to raise $20 million at a $60 million market cap. Tenon is preparing a national commercial launch for its proprietary, FDA cleared surgical implant system for sacroiliac joint fixation and fusion surgery. The company has not generated significant revenues to date.
Holdover Austin Gold (AUST) may also price in the week ahead, with plans to raise $13 million at a $52 million market cap. The company has interests in four properties throughout Nevada, only one of which it considers to be material at this time.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business | Deal Size Market Cap | Price Range Shares Filed | Top Bookrunners |
| Tenon Medical (TNON) Los Gatos, CA | $20M $60M | $4.50 - $5.50 4,000,000 | Benchmark Valuable Capital |
| Launching a surgical implant system for sacroiliac joint fusion procedures. | |||
| Belite Bio (BLTE) San Diego, CA | $36M $145M | $5.50 - $6.50 6,000,000 | Benchmark |
| Phase 3 biotech developing novel therapies for retinal degeneration and metabolic diseases. | |||
| HilleVax (HLVX) Boston, MA | $175M $625M | $16 - $18 10,294,000 | JP Morgan SVB Leerink |
| Phase 2 biotech developing a novel norovirus vaccine in-licensed from Takeda. | |||
| Austin Gold (AUST) Vancouver, Canada | $13M $52M | $4 3,265,000 | Roth Cap. |
| Canadian gold exploration company with four properties in Nevada. | |||
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
Lock-up periods will be expiring for up to 13 companies in the week ahead. For access to lock-up expiration dates, sign up for a free trial of IPO Pro.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/21/2022, the Renaissance IPO Index was down 35.0% year-to-date, while the S&P 500 was down 7.4%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Crowdstrike Holdings (CRWD). The Renaissance International IPO Index was down 26.5% year-to-date, while the ACWX was down 8.0%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.
